Janssen China Announces Four Innovative Medicines Included in National Reimbursement Drug List and Six Products Successfully Renewed

Beijing, December 3, 2021 /PRNewswire/ -- Today, the National Healthcare Security Administration announced the "National Basic Medical Insurance, Work-related Injury Insurance, and Maternity Insurance Drug Catalog (2021 Edition)" (hereinafter referred to as: National Medical Insurance Catalog), which includesUnder Janssen China4An Innovative Drug Included in China's National Medical Insurance Catalog for the First Time, includingDARZALEX®(Daratumumab Injection),Erleada®(Apalutamide Tablets) andStelara®(Ustekinumab Injection),Stelara®(Ustekinumab Injection for Intravenous Infusion) will significantly improve the affordability of innovative drugs for patients with tumors and immune diseases. Moreover, Janssen Pharmaceuticals has6Successful Renewal of Innovative Drug, covering major disease areas such as immunity, infectious diseases, and pulmonary arterial hypertension.

Alvin Zheng, President of Janssen China, said"Janssen's innovative drugs have been included in the National Medical Insurance Catalog, which makes us very pleased and excited. All along, working with the government to enhance the accessibility of innovative drugs has always been a key focus of Janssen China. We also closely cooperate with medical insurance and other people-oriented policies to help achieve social equity and common prosperity, continuously fulfilling our long-term commitment to Chinese patients. As a leading pharmaceutical innovation enterprise, we will continue to collaborate with all partners to address unmet medical needs in China, enabling more patients to access innovative treatment options and contributing to the construction of Healthy China."

Three New Innovative Drugs Listed in the National Medical Insurance Catalog and Their Indications Are as Follows:

1.    Janssen Pharmaceuticals^®(Daratumumab Injection)

2.    Erleada^®(Apalutamide Tablets)

3.    STELARA^®(Ustekinumab Injection)

4.    Stelara^®(Ustekinumab Injection for Intravenous Infusion)

The following are six innovative drugs that have successfully been renewed in the National Medical Insurance Catalog and their indications:

1.    Remicade^®(Infliximab Injection)

2.   Snaire^®(Bedaquiline Fumarate Tablets)

3.   Youtuo Bi^®(Selexipag Tablets)

4.   Opsumit^®(Macitentan Tablets)

5.   Tracleer^®(Bosentan Tablets, Bosentan Dispersible Tablets)

6.   Zewei Ke^®(Miglustat Capsules)

Currently, out of Janssen China's 63 pharmaceutical formulations, 58 have been included in the National Medical Insurance Catalog, covering fields such as oncology, immunology, neurology, pulmonary hypertension, and infectious diseases, addressing China's medical needs.The Most UrgentTherapeutic Areas. In addition to aligning with the national medical insurance catalog policies, Janssen is also actively responding to multi-layered medical security systems, including inclusive insurance and the Greater Bay Area pharmaceuticals and medical devices accessibility policy. Janssen is committed to establishing diverse payment and access models, thereby enhancing affordability for patients in China and continuously striving to benefit patients in China.